Media Thread, page-2844

Roche pulls Tecentriq breast cancer nod after post-approval trial flop

Below is an extract of the above article:

The setback comes at a difficult time for Roche’s oncology business, which has faced eroding sales from biosimilar competition for Avastin, Herceptin and Rituxan. Combined revenue for those drugs fell 39% in 2021, according to the company’s half-year report.

Due to their past history, I am sure Roche is well aware of Leslie Chong's Her-Vaxx and PD1-Vaxx progress. What better way to blow off these biosims than getting an exclusive deal for both Her-Vaxx and PD1-Vaxx with a long patent runway. More importantly, Her-Vaxx, and I pretty sure PD1-Vaxx, will both have better efficacy, safety and tolerability than what is available out there. If Roche with the help of IMU can monopolise those relevant cancer market, it would be worth tens of billions annually!

All we need do now is wait for the IMU science to do all talking.

By the way, Merck's Keytruda is also suffering losing market share to biosims in the same way as what Roche is suffering from. So who knows, a bidding war for our B-Cell tech?